A股上市公司2024年年报收官，十大"盈利王""增长王"浮出水面。 数据显示，剔除金融股影响，2024年，中国石油、中国移动、中国海油、贵州茅台、中国神华、宁德时 代、中国石化、中远海控、中国建筑、比亚迪为A股十大"盈利王"。 剔除金融股及扭亏股影响，2024年，正丹股份、广西能源、思特威-W、华北制药、安迪苏、国机汽 车、三湘印象、德明利、沪光股份、七彩化学为A股十大"增长王"。 十大"盈利王"均计划现金分红 "三桶油"中，中国石油、中国海油均跻身十大"盈利王"。 中国石油2024年实现归母净利润1646.8亿元， 同比增长2.0%；中国海油2024年实现归母净利润1379.36亿元，同比增长11.4%。 十大"盈利王"均计划进行现金分红。贵州茅台2024年实现营业总收入1741.44亿元，同比增长15.66%； 实现归母净利润862.28亿元，同比增长15.38%，公司拟10派276.24元。2024年度贵州茅台将合计派发现 金分红647亿元（其中300亿元已经派发）。 贵州茅台在公告中表示，2025年主要目标是实现营业总收入较上年度增长9%左右，完成固定资产投资 47.11亿元。 此外，宁德时代宣布拟1 ...

Core Viewpoint - Andy Su, a leading global animal nutrition company, reported strong performance in Q1 2025, with significant revenue and profit growth driven by its dual pillar strategy focusing on methionine and specialty products [1][3]. Financial Performance - In Q1 2025, the company achieved revenue of 4.3 billion yuan, a year-on-year increase of 23% [1]. - Gross profit rose by 14% to 1.27 billion yuan, while net profit surged by 67.9% to 465 million yuan [1][3]. - The functional products segment generated revenue of 3.32 billion yuan, reflecting a 29% year-on-year growth, with methionine sales volume increasing by 24% [1][4]. Business Strategy - The company is implementing a "dual pillar" strategy to solidify its leadership in the methionine market while accelerating the development of specialty products [1][5]. - To meet global methionine demand, Andy Su plans to raise up to 3 billion yuan through a private placement to fund four core projects and enhance working capital [5][6]. Production Capacity and R&D Investment - The company is expanding its production capacity, with a new solid methionine project in Fujian province expected to produce 150,000 tons annually, set to commence operations in 2027 [5][6]. - R&D expenditures have been steadily increasing, totaling 1.858 billion yuan over the past five years, with a focus on green production, biotechnology, and digital services [2][6].

Core Viewpoint - The company, Andisu, is undergoing significant capital operations, marking its largest since its reverse merger in 2015, with a focus on expanding its production capacity in the animal nutrition sector [1] Group 1: Company Overview - Andisu specializes in the research, production, and sales of animal nutrition additives, holding a leading position in the industry for several core products [3] - The company's product offerings are categorized into functional products, such as methionine and vitamins, and specialty products aimed at enhancing animal health and feed efficiency [3] Group 2: Investment Projects - The company plans to invest CNY 1.743 billion (approximately USD 246 million) in a solid methionine project with an annual capacity of 150,000 tons, accounting for 46.3% of the total fundraising amount [4] - The project will be located in Quanzhou, Fujian Province, and is expected to commence production in 2027 [4] - The liquid methionine production capacity at Andisu's Nanjing plant is currently the second largest globally, which will create synergies with the new solid methionine expansion [4] Group 3: Financial Performance - In 2024, Andisu is projected to achieve a revenue of CNY 15.53 billion (approximately USD 2.23 billion), representing a year-on-year growth of 17.83% [9] - The net profit attributable to shareholders is expected to reach CNY 1.204 billion (approximately USD 171 million), showing a dramatic increase of 2215% compared to 2023, although this is largely due to a low base effect from the previous year [9] - The company's net profit in 2023 was only CNY 52 million (approximately USD 7.4 million), a decline of nearly 96% from CNY 1.247 billion (approximately USD 178 million) in 2022 [9] Group 4: Market Dynamics - The methionine market is dominated by international giants, with a global market size projected to exceed 1.5 million tons by 2028, while the current domestic production rate is below 30% [3] - The industry has experienced a cyclical nature, with methionine prices significantly influenced by global capacity expansions, leading to an oversupply situation [10] - From 2016 to 2023, the average price of methionine in the domestic market decreased by 34% [10] Group 5: Cost and Profitability - The company's operating costs have risen sharply from CNY 7.465 billion (approximately USD 1.06 billion) in 2016 to CNY 13.669 billion (approximately USD 1.96 billion) in 2024 [12] - Despite efforts to optimize supply chain management, the pressure from rising costs, driven by high prices of key raw materials and global supply chain disruptions, has significantly impacted profitability [12] - The gross margin has decreased from 47.43% in 2016 to 21.38% in 2023, with a recovery to 30.21% anticipated in 2024 [10]

星标 ★ IPO日报 精彩文章第一时间推送 近期，全球动物营养添加剂龙头蓝星安迪苏股份有限公司（600299.SH，下称"安迪苏"）发布公告，公司拟向特定对象发行预计发行数量不超过8 亿股公司股票，募集资金总额不超过30亿元，用于四大核心项目及补充流动资金。 4月16日，该事项获上交所受理。 不过，作为动物必需氨基酸，蛋氨酸市场长期被赢创、住友、诺伟司等国际巨头垄断。兴业证券研报显示，全球蛋氨酸市场规模预计2028年将突破 150万吨，当前国产化率不足30%。 在此次募投项目中，公司拟使用17.43亿元，投入年产能为15万吨的固体蛋氨酸项目，占总募资额的46.3%，进一步扩产。该项目实施地点在福建 省泉州市，预计于2027年投产。 值得关注的是，安迪苏南京工厂的液体蛋氨酸产能已达全球第二，与此次固体蛋氨酸的扩产将形成协同效应。 这是继2015年通过反向收购重组上市后，公司规模最大的资本运作。 制图：佘诗婕 发挥协同效应 据悉，安迪苏主要从事动物营养添加剂的研发、生产及销售。公司在动物饲料添加剂领域中，多个核心产品的产业规模与技术水平处于行业领先地 位。 具体来看，公司产品主要分为两类，包括功能性产品和特种产品 ...

Core Viewpoint - The company, Andisu, is progressing with its private placement fundraising project, aiming to raise up to 3 billion yuan for various strategic initiatives, including functional and specialty product projects, sustainable development, and working capital [1][2]. Group 1: Fundraising and Strategic Development - The private placement aims to raise a total of no more than 3 billion yuan, with net proceeds allocated to functional products, specialty products, sustainable development projects, and working capital [2][3]. - The company has categorized its main business products into functional products, which include methionine, vitamins, and ammonium sulfate, and specialty products, which focus on enhancing animal health and feed quality [2][3]. Group 2: Financial Performance and Recovery - After experiencing a significant decline in performance in 2022 and 2023, the company is expected to return to normal operations in 2024, with projected revenues of 15.534 billion yuan and a net profit of 1.204 billion yuan [1][6]. - The company reported a 24% increase in revenue from functional products in 2024, achieving 11.622 billion yuan, while specialty products generated 3.913 billion yuan, reflecting a 4% growth [2][5]. - The company’s net profit for 2024 is projected to increase by 2208.66% compared to the previous year, indicating a strong recovery [6]. Group 3: Market Position and Growth - The company has increased its market share in methionine from 23% in 2012 to 28% in 2023, solidifying its leadership position in the industry [5]. - The company is expanding its global market presence, with double-digit sales growth in Europe, North America, and Asia in 2024 [3]. - The price of methionine has risen by approximately 8.14% since 2025, which is expected to positively impact the company's performance [3].

Core Viewpoint - The article highlights the recent trend of public fund managers increasing their positions in companies with strong profit growth, particularly in the livestock and energy sectors, as they adjust their portfolios following the disclosure of 2024 annual reports [1][4]. Group 1: Livestock Sector Performance - Companies in the livestock sector, such as Muyuan Foods, have shown significant performance improvements, attracting attention from fund managers. Muyuan Foods reported a revenue of 137.947 billion yuan, a year-on-year increase of 24.43%, and a net profit of 17.881 billion yuan, marking a turnaround from losses [4][5]. - Fund managers have notably increased their holdings in Muyuan Foods, with notable increases from various ETFs managed by Huatai-PineBridge and other funds [4][5]. - The animal nutrition additive producer, Andisu, also saw a revenue of 15.534 billion yuan, up 17.83%, and a net profit of 1.204 billion yuan, reflecting a substantial year-on-year growth of 2208.66% [4][5]. Group 2: High Dividend Stocks - High dividend-paying industry leaders, such as Fuyao Glass, Muyuan Foods, and Baofeng Energy, are favored by institutional investors, with expected cash dividends exceeding 2 billion yuan [7]. - For instance, the waterproofing company Oriental Yuhong saw significant increases in holdings from national social security funds and various mutual funds, indicating strong institutional interest [7]. Group 3: Chemical and Energy Sector Insights - Companies in the chemical and energy sectors, including Chuanjin Nuo and Shanghai Petrochemical, have also reported strong performance, attracting fund manager interest [8][9]. - Fund managers believe that industries facing overcapacity, such as photovoltaics and chemicals, may benefit from policy support aimed at supply-side reforms, potentially leading to a market turning point [9]. - Baofeng Energy, a leader in the coal chemical industry, has seen new major shareholders, indicating growing institutional confidence in the sector [8][9].